Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Value-Based Cancer Care

- PMLiVE

FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision

FDA is requiring Biogen to conduct a new randomised, controlled clinical trial to verify the drug’s clinical benefit for Alzheimer’s patients

- PMLiVE

Sense of belonging

Achieving a good sense of belonging in your teams increases productivity and reduces turnover

- PMLiVE

The rise of the healthcare social media influencer

The consumer industry has long been leveraging the power of social media influencers with enormous success. But can the highly regulated healthcare industry achieve the same results? Daniel Brackins explores...

Avalere Health

- PMLiVE

Vaccine hesitancy eBook

In this e-book, we answer the difficult questions around vaccine hesitancy. Our consultants and commercial experts explore the behavioural science and reveal strategies for improving uptake.

Avalere Health

- PMLiVE

AZ appoints Alexion’s Aradhana Sarin as chief financial officer

Sarin will become AZ's new chief financial officer upon closing of the company’s acquisition of Alexion Pharmaceuticals

- PMLiVE

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

Renal cell carcinoma is the most common form of kidney cancer

Day in a #LucidLife – Meet Jack

Take a look at what it's like working at Lucid Group. Jack discusses his experience of Lucid's Futures Academy, of transitioning to a fully remote workforce in lockdown, Lucid's culture...

Lucid Group Communications Limited

- PMLiVE

Piloting a route to the biosimilars opportunities in Europe

Investigating the EU regulatory hurdles that life sciences companies face as they seek to improve patient access to biosimilar therapy

- PMLiVE

Eli Lilly demonstrates Verzenio win in high-risk breast cancer subset at ASCO

Verzenio plus endocrine therapy reduced the risk of patients developing metastatic disease by 39%

- PMLiVE

Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO

mCRPC patients treated with Lu-PSMA-617 plus best standard of care achieved a 38% reduction in the risk of death

- PMLiVE

Positive results for AZ, Merck & Co’s Lynparza in early breast cancer presented at ASCO

Lynparza reduced the risk of invasive breast cancer recurrence, second cancers or death by 42% in the overall trial population

- PMLiVE

Pushing all the wrong buttons

The technology responses to this pandemic have fallen far short of expectations

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links